Melan-Dx: a knowledge-enhanced vision-language framework improves differential diagnosis of melanocytic neoplasm pathology - Top-Institutions - MDSpire

Melan-Dx: a knowledge-enhanced vision-language framework improves differential diagnosis of melanocytic neoplasm pathology

  • By

  • Jialu Yao

  • Songhao Li

  • Peixian Liang

  • Xiaowei Xu

  • David Elder

  • Zhi Huang

  • January 20, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Dermatopathology
    • Computational Pathology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Dermatopathology
    • Oncology
    • Cancer Research

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Pathology
    • Biomedical Informatics

  • #4

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Dermatology
    • Pathology
    • Cancer Biology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Pathology
    • Oncology

Original Source(s)

Melan-Dx: a knowledge-enhanced vision-language framework improves differential diagnosis of melanocytic neoplasm pathology

  • by Jialu Yao, Songhao Li, Peixian Liang, Xiaowei Xu, David Elder, Zhi Huang

  • January 20, 2026

Related Content

Liver cirrhosis and hepatocellular carcinoma: chronological decoupling of biochemical clearance and mechanical regeneration signals a systems biology hypothesis on programed deconstruction failure

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

Errors in the Table 2

  • May 1, 2026